July 26, 2024
Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies
Belgium-based Confo Therapeutics has secured €60m ($65m) in a Series B financing round to propel its pipeline of G protein-coupled receptor (GPCR)-modulating therapies into clinical development.